Bank of America’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-145,799
| Closed | -$1.33M | – | 8634 |
|
|
2025
Q2 | $1.33M | Sell |
145,799
-58,198
| -29% | -$428K | ﹤0.01% | 5096 |
|
|
2025
Q1 | $1.62M | Sell |
203,997
-112,676
| -36% | -$825K | ﹤0.01% | 4852 |
|
|
2024
Q4 | $1.72M | Sell |
316,673
-355,277
| -53% | -$2.17M | ﹤0.01% | 4577 |
|
|
2024
Q3 | $4.85M | Buy |
671,950
+161,069
| +32% | +$1.47M | ﹤0.01% | 3759 |
|
|
2024
Q2 | $5.55M | Sell |
510,881
-13,714
| -3% | -$176K | ﹤0.01% | 3525 |
|
|
2024
Q1 | $9.83M | Buy |
524,595
+255,044
| +95% | +$5.88M | ﹤0.01% | 2995 |
|
|
2023
Q4 | $5.84M | Sell |
269,551
-227,042
| -46% | -$4.5M | ﹤0.01% | 3428 |
|
|
2023
Q3 | $10.2M | Buy |
496,593
+360,649
| +265% | +$10.4M | ﹤0.01% | 2698 |
|
|
2023
Q2 | $6.39M | Sell |
135,944
-148,057
| -52% | -$7.37M | ﹤0.01% | 3165 |
|
|
2023
Q1 | $11.9M | Buy |
284,001
+36,790
| +15% | +$1.58M | ﹤0.01% | 2645 |
|
|
2022
Q4 | $9.43M | Buy |
247,211
+51,995
| +27% | +$1.99M | ﹤0.01% | 2739 |
|
|
2022
Q3 | $7.64M | Buy |
195,216
+39,295
| +25% | +$1.52M | ﹤0.01% | 2897 |
|
|
2022
Q2 | $5.04M | Sell |
155,921
-85,167
| -35% | -$2.85M | ﹤0.01% | 3390 |
|
|
2022
Q1 | $7.98M | Buy |
241,088
+98,996
| +70% | +$3.72M | ﹤0.01% | 3085 |
|
|
2021
Q4 | $6.04M | Buy |
142,092
+60,790
| +75% | +$2.55M | ﹤0.01% | 3458 |
|
|
2021
Q3 | $3.6M | Sell |
81,302
-26,137
| -24% | -$1.2M | ﹤0.01% | 3890 |
|
|
2021
Q2 | $6.1M | Buy |
107,439
+20,110
| +23% | +$1.42M | ﹤0.01% | 3334 |
|
|
2021
Q1 | $6.54M | Sell |
87,329
-19,802
| -18% | -$1.62M | ﹤0.01% | 3128 |
|
|
2020
Q4 | $9.27M | Buy |
107,131
+25,024
| +30% | +$1.84M | ﹤0.01% | 2551 |
|
|
2020
Q3 | $5.02M | Sell |
82,107
-66,193
| -45% | -$3.35M | ﹤0.01% | 2911 |
|
|
2020
Q2 | $6.17M | Sell |
148,300
-41,828
| -22% | -$1.52M | ﹤0.01% | 2671 |
|
|
2020
Q1 | $5.46M | Buy |
190,128
+2,806
| +1% | +$162K | ﹤0.01% | 2593 |
|
|
2019
Q4 | $13.5M | Sell |
187,322
-51,329
| -22% | -$6.31M | ﹤0.01% | 2252 |
|
|
2019
Q3 | $33.5M | Buy |
238,651
+14,050
| +6% | +$2.35M | 0.01% | 1407 |
|
|
2019
Q2 | $41.1M | Sell |
224,601
-56,141
| -20% | -$9.58M | 0.01% | 1274 |
|
|
2019
Q1 | $44.7M | Buy |
280,742
+121,742
| +77% | +$17.6M | 0.01% | 1178 |
|
|
2018
Q4 | $15.2M | Sell |
159,000
-49,385
| -24% | -$5.65M | ﹤0.01% | 1914 |
|
|
2018
Q3 | $29.4M | Buy |
208,385
+18,621
| +10% | +$2.87M | ﹤0.01% | 1512 |
|
|
2018
Q2 | $29.7M | Buy |
189,764
+102,475
| +117% | +$16.1M | ﹤0.01% | 1487 |
|
|
2018
Q1 | $14.1M | Buy |
87,289
+20,199
| +30% | +$3.43M | ﹤0.01% | 2093 |
|
|
2017
Q4 | $11.1M | Sell |
67,090
-33,222
| -33% | -$3.22M | ﹤0.01% | 2352 |
|
|
2017
Q3 | $6.25M | Buy |
100,312
+51,930
| +107% | +$4.08M | ﹤0.01% | 2968 |
|
|
2017
Q2 | $3.85M | Buy |
48,382
+5,220
| +12% | +$377K | ﹤0.01% | 3279 |
|
|
2017
Q1 | $3.07M | Sell |
43,162
-6,572
| -13% | -$385K | ﹤0.01% | 3495 |
|
|
2016
Q4 | $2.54M | Buy |
49,734
+7,438
| +18% | +$351K | ﹤0.01% | 3567 |
|
|
2016
Q3 | $1.95M | Sell |
42,296
-25,006
| -37% | -$1.02M | ﹤0.01% | 3655 |
|
|
2016
Q2 | $2.03M | Buy |
67,302
+6,904
| +11% | +$230K | ﹤0.01% | 3615 |
|
|
2016
Q1 | $1.94M | Sell |
60,398
-2,331
| -4% | -$82.1K | ﹤0.01% | 3596 |
|
|
2015
Q4 | $3.66M | Buy |
62,729
+27,545
| +78% | +$1.36M | ﹤0.01% | 3255 |
|
|
2015
Q3 | $1.49M | Buy |
35,184
+28,158
| +401% | +$1.74M | ﹤0.01% | 4027 |
|
|
2015
Q2 | $513K | Buy |
7,026
+6,793
| +2,915% | +$437K | ﹤0.01% | 4677 |
|
|
2015
Q1 | $12K | Sell |
233
-67
| -22% | -$2.88K | ﹤0.01% | 6242 |
|
|
2014
Q4 | $11K | Buy |
+300
| New | +$11.2K | ﹤0.01% | 7025 |
|
Other funds holding SAGE
IA
HNB
Bank of America's SAGE Position: Q3 2025 in Review
Bank of America sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 145,799 shares — an estimated $1.33M sold.
Bank of America first reported a position in SAGE in Q4 2014 and held it in 43 quarters. The position peaked at $44.7M in Q1 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Bank of America reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Bank of America sold 145,799 Sage Therapeutics shares in Q3 2025, an estimated $1.33M.
- Bank of America first reported a position in Sage Therapeutics in Q4 2014 and held it in 43 quarters.
- Bank of America's Sage Therapeutics position peaked at $44.7M in Q1 2019.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.